2019


March: Lundbeck enters the hunt for schizophrenia biomarkers

New research consortium aims at developing a standardized method for electronic measurements of the brain that can be used to find biomarkers in schizophrenia. This might lead to the development of new drugs.

February: Lundbeck takes part in a comprehensive initiative to understand the blood-brain barrier

Lundbeck is one of 27 international partners from academia, industry, and small and medium enterprises, that aims to solve the mysteries of the blood-brain barrier.

January: Johan Luthman appointed EVP, Research & Development

Johan is a proven and passionate leader with 28 years of experience in neuroscience and global pharmaceutical research and development. Johan will take up his new position on 1 March 2019.

January: Lundbeck commences usage of artificial intelligence in drug discovery

Once again Lundbeck strengthens its research through a partnership. Together with the US based biotech company Numerate Lundbeck will construct new drug candidates by using artificial intelligence.

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.